M|A|R|K|E|T
POST EVENTS
IHS conducts webinar on 'Assessing Global Healthcare Market Access Risk' It focussed on understanding the conceptual framework of risk assessment, cost/pricing and market trends in healthcare and pharma
A
webinar on 'Assessing Global Healthcare Market Access Risk ' was conducted on November 7, 2013, by IHS. The webinar aimed to give an understanding on the conceptual framework of risk assessment, cost/pricing and market trends pertaining to the healthcare and pharma sectors. Gustav Ando, Director, Healthcare and Pharmaceutical Group and Praful Mehta, Senior Healthcare Analyst, IHS were the speakers. Express Pharma was the Strategic Media Partner to the webinar. Ando gave an overview of the global pharma market and its complexities. He highlighted that the focus has shifted from mature markets to emerging markets. He said that growth in emerging markets are being driven by factors like rising demand, improving healthcare environment, relatively low market access cost base etc. Speaking on the fast growing segments in pharma, Ando informed that great sales growth are expected in areas like obesity, HBV/HCV and rheumatalogy while there will be a decline in cardiology, and CNS markets. He also opined that poor capital allocation is a major concern that can derail the progress of
the pharma sector globally. Continuing with the analysis, Mehta said that while the emerging markets offer a lot of growth opportunities for pharma players, the market condition in each country is different. They are producing unique challenges and hidden opportunities. Hence in order to achieve success in emerging markets it is essential to identify key growth areas; secondly, understand the risks and challenges in the market concerned and lastly, devise strategies to optimise the opportunities and tackle the challenges. He said it is important to understand the target patient population, regulatory environment and healthcare models available so that adequate resources can be deployed to create an effective strategy for the specific market which is being targetted. Ando suggested that risk can be a framework to create an effective strategy that will help to capitalise the opportunities. Moving on to market access, Mehta said that it is driven by a) ability to pay for new drugs; b) willingness to pay for new drugs and c) uncertain random events. He informed that economical, financial and political risks
Tops five challenges in emerging markets, according to IHS ● Lack of reimburse-
●
● ● ●
ment and public funding system Lack of healthcare infrastructure for delivery of healthcare products and services Lack of affordability Price pressures Local competition
IHS recommends six strategies that can be deployed for success. They are: ● Close collaboration
●
● ●
● ●
with governments through effective risk management strategies Sales excellence through own sales force Local manufacturing Distributions through local distributors and wholesalers Targetted key account management Outcome based pricing
largely impact market access to drugs. He also informed that regulatory reforms are also taking place in these markets and sophisticated pharmaconomic models will decide the success in these markets. On the India front, Ando commented that the country's pharma and healthcare sectors are plagued by two major concerns i.e. poor influx of capital and poor healthcare infrastructure. Moreover the country's market is highly regionalised which adds to its complexity. Factors like India's intellectual property policy, compliance issues are seen as barriers to growth by MNC pharma However, he opined that it is a market that cannot be ignored and he foresees that in the coming time “MNC pharma companies would be testing the waters much more”, he said. He also recommended PPPs, regionalised strategies and specialised partnerships and collaborations as a means to achieve more success. He sees significant growth opportunity in the field of branded generics. His final take was that while the healthcare system in India is being transformed, pricing of drugs and reimbursement are areas that need more attention.
Business leaders call for accelerated private sector engagement to improve health in India Focus on the role of private players in achieving Health MDG goals
24
EXPRESS HEALTHCARE
O
n the eve of Children’s Day in India, at a business forum on health called “Reaching the Health Millennium Development Goals (MDG): The Critical Role of India’s Private Sector,” held at the Trident Hotel in Mumbai, business and health leaders called on companies to accelerate efforts to save children’s and mothers’ lives in India. If the business community stepped up its efforts and
targeted key health areas, it could help India achieve global targets for reducing maternal, newborn and child deaths in India and save millions of lives, business leaders said. “In India, a large number of maternal, neonatal and infant deaths that occur are from preventable causes and can be averted by timely interventions, not just by government but civil society and the corporate sector www.expresshealthcare.in
too,” said Nita Ambani, Chairperson of the Reliance Foundation, who delivered an opening keynote address. “This will require forging smart, strong and sustainable partnerships with each other and demolishing sectoral barriers to act as one for the national agenda.” “India has a big challenge to improve health and nutrition overall and especially maternal and child health,” said Vinita Bali,
CEO and MD, Britannia. “We believe business has a significant role to play in driving positive outcomes in these areas and must step up to this challenge.” Actress Priyanka Chopra, UNICEF Goodwill Ambassador, applauded the call for increased private sector action. “This discussion on child and maternal health is crucial, and I congratulate the organisers of this event,” Chopra said. “As part of the DECEMBER 2013